Last reviewed · How we verify
Fixed-duration dexamethasone
Dexamethasone is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and modulating gene expression.
Dexamethasone is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and modulating gene expression. Used for Inflammatory and immune-mediated conditions (specific indication under investigation in phase 3 trial not publicly detailed).
At a glance
| Generic name | Fixed-duration dexamethasone |
|---|---|
| Sponsor | UMC Utrecht |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Dexamethasone is a synthetic glucocorticoid that acts as an agonist at the glucocorticoid receptor, leading to transrepression of pro-inflammatory genes and transactivation of anti-inflammatory genes. The 'fixed-duration' formulation likely refers to a predetermined treatment course designed to minimize long-term corticosteroid exposure while maintaining therapeutic benefit. This approach aims to reduce cumulative adverse effects associated with prolonged corticosteroid use.
Approved indications
- Inflammatory and immune-mediated conditions (specific indication under investigation in phase 3 trial not publicly detailed)
Common side effects
- Hyperglycemia
- Insomnia
- Increased infection risk
- Mood changes
- Hypertension
- Osteoporosis (with prolonged use)
Key clinical trials
- Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma (PHASE3)
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1, PHASE2)
- AKY15-HK-301_NEPA Study (PHASE2)
- Platform of Randomized Adaptive Clinical Trials in Critical Illness (NA)
- Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (PHASE1, PHASE2)
- Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents (PHASE3)
- CGM-Based Glycemic Analysis After ESI
- Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |